RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost remission in tough lymphoma cases
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy and a stem cell transplant can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatment. About 25 adults will receive the combination therapy. The goa…
Matched conditions: RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 17, 2026 01:51 UTC
-
New drug cocktail aims to boost remission before stem cell transplant
Disease control Recruiting nowThis study tests a two-step treatment for adults with large B-cell lymphoma that came back or didn't respond to initial therapy. First, participants receive tafasitamab (an antibody) plus lenalidomide, then a chemotherapy combo (ICE) plus tafasitamab. The goal is to see if this a…
Matched conditions: RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Could a poop pill make cancer therapy work better?
Disease control Recruiting nowThis study tests whether a fecal transplant from healthy donors can repair gut damage caused by antibiotics and chemotherapy in lymphoma patients receiving CAR T-cell therapy. About 56 adults with relapsed or hard-to-treat lymphoma will be randomly assigned to get either the tran…
Matched conditions: RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Double punch: experimental drug may boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study tests whether adding the drug odronextamab before and after standard CAR-T cell therapy can help people with a type of aggressive lymphoma (DLBCL) that has returned or not responded to prior treatments. About 34 adults who have already tried at least two other therapie…
Matched conditions: RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 12, 2026 13:40 UTC